Dermisonics, Inc. (DMSI) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerDermisonics, Inc. (DMSI) trades at $0.00003. Dermisonics, Inc. specializes in ultrasonic transdermal drug-delivery technologies, focusing on its innovative U-Strip product for needle-free drug delivery. Sector: Healthcare.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for DMSI: DMSI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Dermisonics, Inc. (DMSI) Healthcare & Pipeline Overview
Dermisonics, Inc. is a pioneering healthcare company focused on developing ultrasonic transdermal drug delivery systems, particularly its U-Strip, designed to facilitate the needle-free administration of large molecular drugs, such as insulin, enhancing patient compliance and treatment outcomes.
What Is the Investment Thesis for DMSI?
Dermisonics, Inc. represents a unique investment opportunity in the healthcare sector, particularly within the transdermal drug delivery market. The company’s flagship product, the U-Strip, is poised to capture a significant share of the growing insulin delivery market, which is projected to reach $30 billion by 2027. With an increasing global diabetic population, the demand for needle-free delivery systems is expected to rise substantially. Dermisonics' innovative technology offers a competitive advantage, as it addresses the pain points associated with traditional insulin delivery methods. The company’s focus on research and development, along with strategic partnerships, could further enhance its market position. However, investors should be aware of the inherent risks in the healthcare sector, including regulatory hurdles and competition from established players. As Dermisonics advances its product through clinical trials and regulatory approvals, key milestones in the next 12 to 24 months could significantly influence its market valuation.
Based on FMP financials and quantitative analysis
DMSI Key Highlights
Market Cap: $0.00B, indicating a current lack of trading activity.
- P/E Ratio: -0.00, reflecting the company's current unprofitability.
- Beta: -244.38, suggesting extreme volatility in trading.
- Dividend Yield: None, as the company does not currently distribute dividends.
- Shell Risk: Detected, indicating potential concerns regarding the company's operational status.
Who Are DMSI's Competitors?
What Are DMSI's Key Strengths?
Innovative transdermal drug delivery technology.
- Strong focus on patient compliance and comfort.
- Niche market positioning with potential for growth.
What Are DMSI's Weaknesses?
Current lack of trading activity and market capitalization.
- Uncertain regulatory landscape for new medical devices.
- Limited financial resources for extensive R&D.
What Are the Key Risks for DMSI?
Negative return on equity (-32.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles that could impact product timelines.
- Intense competition from established players in the transdermal drug delivery market.
- Market volatility affecting investor confidence and trading activity.
What Are DMSI's Competitive Advantages?
- Innovative technology that addresses pain points in traditional drug delivery methods.
- Focus on large molecular drugs, a niche market with specific needs.
- Potential for strong partnerships with healthcare institutions and pharmaceutical companies.
What Does DMSI Do?
Founded in 2000, Dermisonics, Inc. has established itself as an innovator in the healthcare sector, specifically in the medical specialties industry. Originally known as Second Stage Ventures, Inc., the company rebranded to Dermisonics, Inc. in October 2004 to better reflect its focus on advanced drug delivery technologies. The company is headquartered in Irvine, California, and specializes in the development, testing, and commercialization of its flagship product, the U-Strip. This active transdermal patch is designed to deliver drugs with large molecular structures, such as insulin, directly into the bloodstream without the need for needles. Dermisonics aims to improve patient compliance and comfort by providing a needle-free alternative for drug administration. The U-Strip represents a significant advancement in drug delivery technology, catering to the growing demand for more patient-friendly healthcare solutions. As the company continues to innovate, it seeks to carve out a significant market share in the rapidly evolving field of transdermal drug delivery, positioning itself as a leader in this niche market.
What Products and Services Does DMSI Offer?
- Manufacture ultrasonic transdermal drug delivery technologies.
- Develop and commercialize the U-Strip for needle-free drug delivery.
- Focus on large molecular drugs, such as insulin.
- Conduct research and testing to enhance drug delivery efficacy.
- Aim to improve patient compliance and comfort with innovative solutions.
- Position itself as a leader in the transdermal drug delivery market.
How Does DMSI Make Money?
- Generate revenue through the sale of transdermal drug delivery devices.
- Partner with pharmaceutical companies for product development and commercialization.
- Focus on research and development to innovate and expand product offerings.
What Industry Does DMSI Operate In?
The medical specialties industry is experiencing significant growth, driven by advancements in technology and an increasing demand for innovative healthcare solutions. The global transdermal drug delivery market is projected to grow at a CAGR of 8.3%, reaching approximately $10 billion by 2026. Dermisonics, Inc. operates in a competitive landscape, facing challenges from established players and emerging startups. Competitors such as AMPE, BLMS, BTTX, CENBF, and IMRSQ are also exploring similar technologies, emphasizing the need for Dermisonics to differentiate its offerings and maintain a strong market position.
Who Are DMSI's Key Customers?
- Healthcare providers seeking advanced drug delivery solutions.
- Pharmaceutical companies interested in partnerships for drug delivery technologies.
- Patients requiring needle-free drug administration options.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Dermisonics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Dermisonics, Inc. stands at -32.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -25.3%, showing how much profit it generates from its asset base. A current ratio of 0.14 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Dermisonics, Inc. operates in the Healthcare sector. It is headquartered in Irvine, US. The company is led by CEO Bruce H. Haglund. DMSI has traded publicly since 2003.
DMSI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
DMSI Latest News
-
Stocks That Hit 52-Week Lows On Friday
· Dec 13, 2019
DMSI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for DMSI.
Price Targets
Wall Street price target analysis for DMSI.
DMSI MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for DMSI; grades run from A+ (80-100) to F (below 30).
Who Are DMSI's Competitors?
Leadership: Bruce H. Haglund
CEO
Bruce H. Haglund has a rich background in the healthcare sector, with extensive experience in medical technology development. He has held various leadership positions in healthcare companies, focusing on innovative solutions and market growth. His educational background includes degrees in relevant fields that support his role in leading Dermisonics.
Track Record: Under Bruce H. Haglund's leadership, Dermisonics has focused on advancing its transdermal drug delivery technology, particularly the U-Strip. His strategic vision has guided the company through its rebranding and positioned it for future growth.
DMSI OTC Market Information
The OTC Other tier includes companies that do not meet the financial standards for higher tiers like NYSE or NASDAQ. This tier is typically characterized by lower trading volumes and less stringent reporting requirements, which can lead to increased volatility and risk for investors.
- OTC Tier: OTC Other
- Limited financial reporting can obscure the company's financial health.
- Low trading volume may lead to increased price volatility.
- Shell risk indicates potential operational concerns.
- Verify the company's product development status and pipeline.
- Assess the regulatory approval process for the U-Strip.
- Evaluate the competitive landscape and market positioning.
- Review any available financial statements or disclosures.
- Investigate the company's leadership and strategic direction.
- Established history since 2000 with a focus on innovation.
- Rebranding to Dermisonics, Inc. reflects a commitment to its core business.
- Engagement in the development of advanced medical technologies.
Dermisonics, Inc. Healthcare Stock: Key Questions Answered
What are the main risks for DMSI?
Dermisonics, Inc. faces several risks, including regulatory challenges that could delay product approvals and market entry. Additionally, the company operates in a competitive landscape with established players, which may impact its market share and growth potential.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited trading activity and financial disclosures may affect investment decisions.